The role of PPAR-? antagonism on losartan ameliorating effect on lung injury and systemic inflammation induced by LPS in mice
M. Boskabady (Mashhad, Islamic Republic of Iran), V. Rouki (Mashhad, Islamic Republic of Iran), S. Saadat (Mashhad, Islamic Republic of Iran), A. Memarzia (Mashhad, Islamic Republic of Iran), H. Salmani (Mashhad, Islamic Republic of Iran), Z. Gholamnezhad (Mashhad, Islamic Republic of Iran), M. Hosseini (Mashhad, Islamic Republic of Iran)
Source: International Congress 2022 – In vivo and in vitro studies of airway diseases
Session: In vivo and in vitro studies of airway diseases
Session type: Thematic Poster
Number: 3163
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Boskabady (Mashhad, Islamic Republic of Iran), V. Rouki (Mashhad, Islamic Republic of Iran), S. Saadat (Mashhad, Islamic Republic of Iran), A. Memarzia (Mashhad, Islamic Republic of Iran), H. Salmani (Mashhad, Islamic Republic of Iran), Z. Gholamnezhad (Mashhad, Islamic Republic of Iran), M. Hosseini (Mashhad, Islamic Republic of Iran). The role of PPAR-? antagonism on losartan ameliorating effect on lung injury and systemic inflammation induced by LPS in mice. 3163
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|